Showing 1 - 10 results of 10 for search 'Yijun Jia', query time: 0.06s
Refine Results
-
1
-
2
-
3
An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell L... by Qing Chen, Ziyi Weng, Yunshu Lu, Yijun Jia, Longlong Ding, Fang Bai, Meixin Ge, Qing Lin, Kejin Wu
Published 2017-01-01
Article -
4
-
5
-
6
Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics by Bing Cao, Chenbo Sun, Rui Bi, Zebing Liu, Yijun Jia, Wenli Cui, Menghong Sun, Baohua Yu, Xiaoqiu Li, Xiaoyan Zhou
Published 2024-04-01
Article -
7
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer by Ruoshuang Han, Haoyue Guo, Jinpeng Shi, Sha Zhao, Yijun Jia, Xiaozhen Liu, Yiwei Liu, Lei Cheng, Chao Zhao, Xuefei Li, Caicun Zhou
Published 2024-04-01
Article -
8
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer by Ruoshuang Han, Haoyue Guo, Jinpeng Shi, Sha Zhao, Yijun Jia, Xiaozhen Liu, Yiwei Liu, Lei Cheng, Chao Zhao, Xuefei Li, Caicun Zhou
Published 2024-09-01
Article -
9
Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer by Lei Cheng, Caicun Zhou, Tao Jiang, Fei Zhou, Shengxiang Ren, Hongcheng Liu, Xinyu Liu, Xiaoxia Chen, Xuefei Li, Chao Zhao, Meng Qiao, Haowei Wang, Yijun Jia
Published 2022-12-01
Article -
10
Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC by Sangtian Liu, Fengying Wu, Xuefei Li, Chao Zhao, Yijun Jia, Keyi Jia, Ruoshuang Han, Meng Qiao, Wei Li, Jia Yu, Fei Zhou, Anwen Xiong, Bin Chen, Jue Fan, Shengxiang Ren, Caicun Zhou
Published 2021-03-01
Article